2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Hepatocellular
147
Carcinoma, Renal Cell
37
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Neoplasms
28
Cholangiocarcinoma
26
Endometrial Neoplasms
19
Thyroid Neoplasms
17
Liver Neoplasms
17
Melanoma
15
Stomach Neoplasms
13
Carcinoma, Non-Small-Cell Lung
13
Biliary Tract Neoplasms
13
Recurrence
9
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
8
Ovarian Neoplasms
8
Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
5
Thyroid Carcinoma, Anaplastic
5
Small Cell Lung Carcinoma
5
Neuroendocrine Tumors
5
Esophageal Squamous Cell Carcinoma
5
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Kidney Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma
4
Adenocarcinoma
4
Thyroid Cancer, Papillary
3
Interventions
lenvatinib
1
camrelizumab
1
apatinib
1
Cyclophosphamide
1
Albumin-Bound Paclitaxel
1
ALT-803
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Triple Negative Breast Cancer
×
lenvatinib
×
Clear all
NCT06849492
2025-02-27
SHIFT-001
Fudan University
Phase 2
Not yet recruiting
120 enrolled